Jereczek-Fossa Barbara A, Alterio Daniela, Jassem Jacek, Gibelli Bianca, Tradati Nicoletta, Orecchia Roberto
Department of Radiation Oncology, European Institute of Oncology, 435 via Ripamonti, 20141 Milan, Italy.
Cancer Treat Rev. 2004 Jun;30(4):369-84. doi: 10.1016/j.ctrv.2003.12.003.
Despite their specific functional consequences, radiotherapy-induced thyroid abnormalities remain under-estimated and underreported. These sequelae may include primary or central hypothyroidism, thyroiditis, Graves' disease, euthyroid Graves' ophthalmopathy, benign adenomas, multinodular goitre and radiation-induced thyroid carcinoma. Primary hypothyroidism, the most common radiation-induced thyroid dysfunction, affects 20-30% of patients administered following curative radiotherapy to the neck region, with approximately half of the events occurring within the first 5 years after therapy. The relative risk of radiation-induced cancer (mainly well-differentiated tumours) is 15-53-fold higher than in non-irradiated population. The aetiology of radiation-induced thyroid injury includes vascular damage, parenchymal cell damage and auto-immune reactions. Total radiotherapy dose, irradiated volume of the thyroid gland, and the extent of prior thyroid resection are among the most important factors associated with the risk of hypothyroidism. The contribution of other treatment modalities (chemotherapy, endocrine therapy) as well as patient- and tumour-related factors is less clear. Reduction in radiation dose to the thyroid gland and hypothalamic/pituitary complex should be attempted whenever possible. New radiotherapy techniques, such as stereotactic radiosurgery, three-dimensional conformal irradiation, intensity modulated radiotherapy and proton therapy allow generally better dose distribution with lower dose to the non-target organs. The diagnostic approach to thyroid radiation injury includes baseline thyroid function assays in all patients undergoing thyroid or parasellar irradiation. Recommended follow-up procedures include at least annual evaluation with a history for symptoms of thyroid dysfunction, clinical examination, and measurement of thyroid hormones and thyrotropin. Management of overt hypothyroidism is based on hormone replacement therapy. Thyroid hormone therapy is also recommended in cases of subclinical hypothyroidism. Treatment of other radiation-induced thyroid disorders (thyroiditis, Graves' disease, thyroid cancer) is similar to that employed in spontaneously occurring conditions. Further improvements in radiotherapy techniques and progress in endocrine diagnostics and therapy may allow better prevention and management of radiation-related thyroid injury.
尽管放疗引起的甲状腺异常具有特定的功能后果,但仍未得到充分认识和报告。这些后遗症可能包括原发性或中枢性甲状腺功能减退、甲状腺炎、格雷夫斯病、甲状腺功能正常的格雷夫斯眼病、良性腺瘤、多结节性甲状腺肿和放射性甲状腺癌。原发性甲状腺功能减退是最常见的放疗引起的甲状腺功能障碍,在接受颈部根治性放疗的患者中,有20% - 30%会受到影响,约一半的病例发生在治疗后的前5年内。放射性癌症(主要是高分化肿瘤)的相对风险比未接受放疗的人群高15 - 53倍。放射性甲状腺损伤的病因包括血管损伤、实质细胞损伤和自身免疫反应。总放疗剂量、甲状腺的照射体积以及先前甲状腺切除的范围是与甲状腺功能减退风险相关的最重要因素。其他治疗方式(化疗、内分泌治疗)以及患者和肿瘤相关因素的作用尚不清楚。应尽可能尝试降低对甲状腺和下丘脑/垂体复合体的辐射剂量。新的放疗技术,如立体定向放射外科、三维适形放疗、调强放疗和质子治疗,通常能实现更好的剂量分布,对非靶器官的剂量更低。甲状腺辐射损伤的诊断方法包括对所有接受甲状腺或鞍旁放疗的患者进行基线甲状腺功能检测。推荐的随访程序包括至少每年进行一次评估,询问甲状腺功能障碍症状、进行临床检查以及测量甲状腺激素和促甲状腺激素。显性甲状腺功能减退的治疗基于激素替代疗法。亚临床甲状腺功能减退的病例也建议进行甲状腺激素治疗。其他放射性甲状腺疾病(甲状腺炎、格雷夫斯病、甲状腺癌)的治疗与自然发生情况的治疗相似。放疗技术的进一步改进以及内分泌诊断和治疗的进展可能会更好地预防和管理与辐射相关的甲状腺损伤。